Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

2020
- ASCO 2020 - Lung Cancer
2019
- ASH 2019 - CLL
- ASCO 2019 - CLL
2018
- ASH 2018 CLL
- ID Week 2018
2017
2016
- ASH 2016 - Chronic Lymphocytic Leukemia
- ASH 2016 - Multiple Myeloma

Evaluation of the PI3Kδ Inhibitor ME-401 in Patients with Relapsed/Refractory Follicular Lymphoma

Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory CLL

Conceptual Model of CLL

A Systematic Review of the Efficacy of Ibrutinib-Based Combination Therapy for Mantle-Cell Lymphoma

SYK Inhibition with Fostamatinib in Waldenström’s Macroglobulinemia

Ibrutinib Maintenance Following Induction for Untreated MCL: Initial Safety Report

Phase 1/2 Trial of Cirmtuzumab plus Ibrutinib: Planned Analysis of Phase 1 CLL Cohorts

The ZUMA-8 Phase 1/2 Multicenter Study Evaluating KTE-X19 in Patients with Relapsed/Refractory CLL

A Phase 2 Study Investigating Umbralisib Monotherapy in Patients with Relapsed/Refractory MZL

2
3
4
5
6
7
8

Page 5 of 25
Results 41 - 50 of 242

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.